Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nitric oxide inhalation - INOpulse - Bellerophon Therapeutics

Drug Profile

Nitric oxide inhalation - INOpulse - Bellerophon Therapeutics

Alternative Names: Inhaled nitric oxide - Bellerophon; inhaled NO - Bellerophon; iNO- Bellerophon; Nitric oxide-INOpulse®

Latest Information Update: 27 Aug 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ikaria Holdings
  • Developer Bellerophon Therapeutics
  • Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antifibrotics; Antifungals; Antihypertensives; Antivirals; Cardiovascular therapies; Diagnostic agents; Free radicals; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Guanylate cyclase stimulants; Nitric oxide donors; Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension; Idiopathic pulmonary fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Phase III COVID 2019 infections; Pulmonary arterial hypertension
  • Phase II/III Pulmonary hypertension
  • Phase II Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis

Most Recent Events

  • 21 Aug 2020 Bellerophon Therapeutics withdraws its planned phase II NO-COVER trial in COVID-2019 infection, due to IRB and FDA reviews deferred, in USA (NCT04398290)
  • 13 Jul 2020 Efficacy and adverse events data from a clinical study in COVID-2019 infections released by Bellerophon Therapeutics
  • 11 Jul 2020 Phase-III clinical trials in COVID-2019 infections in USA (Inhalation) (NCT04421508)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top